🚀 VC round data is live in beta, check it out!
R&G PharmaStudies Valuation Multiples
Discover revenue and EBITDA valuation multiples for R&G PharmaStudies and similar public comparables like PolyPeptide, Oxford BioMedica, Gubra, Fortrea and more.
R&G PharmaStudies Overview
About R&G PharmaStudies
R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.
Founded
2008
HQ
Employees
N/A
Website
Financials (LTM)
EV
$817M
R&G PharmaStudies Financials
R&G PharmaStudies reported last 12-month revenue of $115M and EBITDA of $25M.
In the same LTM period, R&G PharmaStudies generated $43M in gross profit, $25M in EBITDA, and $20M in net income.
Revenue (LTM)
R&G PharmaStudies P&L
In the most recent fiscal year, R&G PharmaStudies reported revenue of $108M and EBITDA of $29M.
R&G PharmaStudies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $115M | XXX | $108M | XXX | XXX | XXX |
| Gross Profit | $43M | XXX | $40M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | $25M | XXX | $29M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $20M | XXX | $20M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
R&G PharmaStudies Stock Performance
R&G PharmaStudies has current market cap of $1B, and enterprise value of $817M.
Market Cap Evolution
R&G PharmaStudies' stock price is $10.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $817M | $1B | 0.0% | XXX | XXX | XXX | $0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialR&G PharmaStudies Valuation Multiples
R&G PharmaStudies trades at 7.1x EV/Revenue multiple, and 32.6x EV/EBITDA.
EV / Revenue (LTM)
R&G PharmaStudies Financial Valuation Multiples
As of March 7, 2026, R&G PharmaStudies has market cap of $1B and EV of $817M.
Equity research analysts estimate R&G PharmaStudies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
R&G PharmaStudies has a P/E ratio of 52.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $817M | XXX | $817M | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBITDA | 32.6x | XXX | 28.5x | XXX | XXX | XXX |
| EV/EBIT | 35.7x | XXX | 37.6x | XXX | XXX | XXX |
| EV/Gross Profit | 19.0x | XXX | 20.4x | XXX | XXX | XXX |
| P/E | 52.1x | XXX | 52.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 41.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified R&G PharmaStudies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
R&G PharmaStudies Margins & Growth Rates
R&G PharmaStudies' revenue in the last 12 month grew by 11%.
R&G PharmaStudies' rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
R&G PharmaStudies' rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
R&G PharmaStudies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | (15%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 50% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
R&G PharmaStudies Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PolyPeptide | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford BioMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Gubra | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortrea | XXX | XXX | XXX | XXX | XXX | XXX |
| AbCellera | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
R&G PharmaStudies M&A Activity
R&G PharmaStudies acquired XXX companies to date.
Last acquisition by R&G PharmaStudies was on XXXXXXXX, XXXXX. R&G PharmaStudies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by R&G PharmaStudies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialR&G PharmaStudies Investment Activity
R&G PharmaStudies invested in XXX companies to date.
R&G PharmaStudies made its latest investment on XXXXXXXX, XXXXX. R&G PharmaStudies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by R&G PharmaStudies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout R&G PharmaStudies
| When was R&G PharmaStudies founded? | R&G PharmaStudies was founded in 2008. |
| Where is R&G PharmaStudies headquartered? | R&G PharmaStudies is headquartered in China. |
| Is R&G PharmaStudies publicly listed? | Yes, R&G PharmaStudies is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of R&G PharmaStudies? | R&G PharmaStudies trades under 301333 ticker. |
| When did R&G PharmaStudies go public? | R&G PharmaStudies went public in 2022. |
| Who are competitors of R&G PharmaStudies? | R&G PharmaStudies main competitors are PolyPeptide, Oxford BioMedica, Gubra, Fortrea. |
| What is the current market cap of R&G PharmaStudies? | R&G PharmaStudies' current market cap is $1B. |
| What is the current revenue of R&G PharmaStudies? | R&G PharmaStudies' last 12 months revenue is $115M. |
| What is the current revenue growth of R&G PharmaStudies? | R&G PharmaStudies revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of R&G PharmaStudies? | Current revenue multiple of R&G PharmaStudies is 7.1x. |
| Is R&G PharmaStudies profitable? | Yes, R&G PharmaStudies is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of R&G PharmaStudies? | R&G PharmaStudies' last 12 months EBITDA is $25M. |
| What is R&G PharmaStudies' EBITDA margin? | R&G PharmaStudies' last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of R&G PharmaStudies? | Current EBITDA multiple of R&G PharmaStudies is 32.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.